Multiple Sclerosis: Update Bulletin [March 2016]
Gain new KOL insights on the latest events happening in multiple sclerosis (MS):
Topics covered include opinions about the discontinuation of Teva’s/Active Biotech’s higher-dose laquinimod Phase III studies; reactions to European and Canadian regulatory authority recommendations designed to inform physicians and patients about the increased risk of progressive multifocal leukoencephalopathy (PML) and basal cell carcinoma associated with Novartis’ Gilenya (fingolimod), as well as opinions on GeNeuro’s GNbAC1 antibody undergoing Phase IIb evaluation in relapsing remitting multiple sclerosis.
Key Questions Answered in this Update Bulletin:
Topics covered include opinions about the discontinuation of Teva’s/Active Biotech’s higher-dose laquinimod Phase III studies; reactions to European and Canadian regulatory authority recommendations designed to inform physicians and patients about the increased risk of progressive multifocal leukoencephalopathy (PML) and basal cell carcinoma associated with Novartis’ Gilenya (fingolimod), as well as opinions on GeNeuro’s GNbAC1 antibody undergoing Phase IIb evaluation in relapsing remitting multiple sclerosis.
Key Questions Answered in this Update Bulletin:
- How do KOLs feel about the continuation of lower-dose laquinimod studies?
- How optimistic are KOLs regarding laquinimod’s approval?
- What are KOLs’ reactions to European and Canadian recommendations designed to inform physicians and patients about the increased risk of progressive multifocal leukoencephalopathy (PML) and basal cell carcinoma associated with Novartis’ Gilenya (fingolimod)?
- What impact will these label changes have on prescriptions of Gilenya?
- What threats will Gilenya face in the future?
- How optimistic are KOLs about GeNeuro’s GNbAC1 antibody undergoing Phase IIb evaluation in relapsing remitting multiple sclerosis?
